Source: Canada Revenue Agency.

Canada Revenue Agency (CRA) workers are back on the job Friday following a tentative deal was reached between their union and the federal government.

The Public Service Alliance of Canada’s (PSAC) Union of Taxation Employees, which represents CRA staff, stated that it had reached a tentative deal with the federal government that includes wage increases totalling 12.6 per cent over four years.

In a news release, the CRA said that this proposed agreement includes an 11.5 per cent wage increase over four years, with a 0.5 per cent allowance in the third year, and a one-time $2,500 bonus for employees.

The CRA said the agreement addresses all key priorities put forward by the PSAC-UTE and includes improved provisions around leave with pay for family-related responsibilities. It also includes measures to further support employment equity, diversity, and inclusion, such as a new benefit for Indigenous employees who will now have access to paid leave to participate in traditional practices.

The labour deal was reached with 35,000 revenue agency employees, who were on strike for more than two weeks, putting an end to a strike that had slowed the processing of annual tax returns.

The tentative agreement is subject to ratification by PSAC-UTE membership. Details of the tentative agreement to its members and organize ratification vote sessions in the coming weeks.

This was a similar deal to one struck earlier this week between 120,000 federal employees.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.

More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.